Click on the title for more information (where available).
Frampton, G.K., Shepherd, J., Pickett, K. et al. Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. Trials 21, 478 (2020).
Dickson, R., Boland, A., Duarte, R. et al. EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Appl Health Econ Health Policy (2018).
Shepherd J, Frampton GK, Pickett K, Wyatt JC (2018) Peer review of health research funding proposals: A systematic map and systematic review of innovations for effectiveness and efficiency. PLoS ONE 13(5).
O'Connor AM, Lovei GL, Eales J, Frampton GK, Glanville J, Pullin AS, Sargeant J; Implementation of systematic reviews in EFSA scientific outputs workflow. Supporting Publications 2012:EN-367 [36 pp.]
Shepherd J. Judgment, Resources, and Complexity: A Qualitative Study of the Experiences of Systematic Reviewers of Health Promotion. Eval Health Prof. 2012 May 21.
Harris P, Takeda A, Loveman E, Hartwell D. Time to full publication of studies of anti-cancer drugs for breast cancer, and the potential for publication bias. International Journal of Technology Assessment in Health Care 2010;26(1):110-6.
Oliver S, Bagnall AM, Thomas J, Shepherd J, Sowden A, White I, et al. Randomised controlled trials for policy interventions: a review of reviews and meta-regression. Health Technology Assessment 2010;14(16).
Frampton G and Shepherd J. The (ab)use of symptom scores in asthma clinical trials: evidence from a systematic review. Journal of Epidemiology and Community Health 63[Supplement 2], A17. 2009.
Frampton GK, Shepherd J, Dorne JLCM. Demographic data in asthma clinical trials: a systematic review with implications for generalizing trial findings and tackling health disparities. Social Science & Medicine 2009;69(8):1147-54.
Shepherd J. Assessing quality in systematic reviews of the effectiveness of health promotion and public health: Areas of consensus and dissension. Oral presentation to the 17th Cochrane Colloquium, Singapore, 11th to 14th October 2009. 2009.
Frampton GK and Shepherd J. Ambiguity of study population analysis and reporting in asthma clinical trials. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitsweisen 102[Supplement VI], 76-77. 2008.
Gospodarevskaya, E. The Tale of Two Islands. A comparison of approaches towards HTA in England and Australia. A personal view. V Annual meeting HTAi 2008, July, Toronto, Canada. 2008.
Harris P, Takeda A, Loveman E, and Hartwell D. Time to full publication of studies of anti-cancer drug for breast cancer, and the potential for publication bias. National Cancer Research Institute conference 2008.Abstract B33. 2008.
Raftery J, Bryant J, Powell J, Kerr C, Hawker S. Payment to healthcare professionals for patient recruitment to trials. Health Technology Assessment 2008;12(10).
Takeda A, Loveman E, Harris P, Hartwell D, Welch K. Time to full publication of studies of novel chemotherapy drugs for breast cancer and the potential for publication bias: a short systematic review. Health Technology Assessment 2008;12(32).
Shepherd J, Bagnall AM, Colquitt J, Dinnes J, Duffy S, and Sowden A. 'Sometimes similar, sometimes different': a systematic review of meta-analyses of randomised and non-randomised policy intervention studies (poster presentation). XIV Cochrane Colloquium . 2006.
Bryant J, Powell J. Payment to healthcare professionals for patient recruitment to trials: a systematic review. British Medical Journal 2005;331:1377-8.
Waugh N, Royle P, Shepherd J, and Loveman E. Should there be Cochrane reviews of disease aetiology? A discussion poster at the 13th Cochrane Colloquium, Melbourne, 22-26 October, 2005.
Bryant J, Loveman E, Cave C, Chase D, Milne R. Endocrinology trial design: Adverse event reporting in randomised controlled trials of recombinant human GH in GH-deficient adults. Journal of Endocrinology 2002;175:545-52.